Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15109
UPID:
RAGE_HUMAN
Alternative names:
Receptor for advanced glycosylation end products
Alternative UPACC:
Q15109; A2BFI7; A6NKF0; A7Y2U9; B0V176; Q15279; Q3L1R4; Q3L1R5; Q3L1R6; Q3L1R7; Q3L1R8; Q3L1S0; Q86SN1; Q9H2X7; Q9Y3R3; V5R6A3
Background:
The Advanced glycosylation end product-specific receptor (RAGE) is a cell surface receptor that recognizes a variety of endogenous ligands. These include advanced glycation end products, S100 proteins, and HMGB1, among others. RAGE plays a pivotal role in sensing stress signals and mediating inflammatory responses by activating NF-kappa-B, leading to the production of pro-inflammatory cytokines.
Therapeutic significance:
Given its central role in inflammation and stress response, targeting RAGE could offer novel therapeutic avenues in treating diseases characterized by chronic inflammation, such as diabetes, neurodegenerative disorders, and cancers. Understanding the role of RAGE could open doors to potential therapeutic strategies.